Latest FDA news update... Jul 16
Hoth Therapeutics, Inc. a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001 ... Jan 01
CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, is well-tolerated and active in patients with T-cell lymphoma... Dec 07
Novellus Therapeutics exclusively licenses induced mesenchymal stem cells (iMSCs) to NoveCite for COVID-19 related acute respiratory distress syndrome (ARDS) and other acute respiratory conditions ... Oct 13
Citius Pharmaceuticals achieves chemical manufacturing and control milestones for Mino-Lok ... Sep 22
The company tested 40 healthy participants in the Phase 1 trial who were given two shots, four weeks apart, of the vaccine, called INO-4800, ... May 21
-Advertisements-
.jpeg)
Friday, November 22, 2024
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)